10x Genomics has partnered with the Cancer Research Institute on a multi-phase program to generate single-cell and spatial data from over 20,000 tumor and immune samples, starting with a 3,000-sample pilot led by researchers at University of Pennsylvania, Stanford and Memorial Sloan Kettering Cancer Center. Using the Chromium single-cell and Xenium spatial platforms, data will benchmark early AI models, identify predictive cellular and microenvironmental features, then scale to a full phase profiling more than 500 million cells with the high-throughput Chromium Flex assay. Investors should note that this collaboration leverages 10x’s consumable-driven revenue model and expands its addressable market in translational immuno-oncology, positioning the company to capture a growing share of multi-year research budgets focused on next-generation immunotherapies and vaccine discovery.

In a separate initiative, 10x Genomics and Dana-Farber Cancer Institute will analyze tumor specimens from hundreds of patients with major solid tumors—spanning antibody-drug conjugates, radioligand therapies, bispecifics and checkpoint inhibitors—to uncover biomarkers linked to treatment response and resistance. Employing the Chromium Flex single-cell assay alongside the Xenium spatial platform, the teams will generate integrated cellular and spatial maps, correlating them with known clinical outcomes. The partners will also co-develop a CLIA-certified laboratory, laying the groundwork for future diagnostics revenue streams by validating assays under regulatory standards and establishing a clinical reporting framework for oncologists.

10x Genomics has launched a collaboration with Brigham & Women’s Hospital to enroll 1,000 patients with rheumatoid arthritis, lupus and giant cell arteritis, plus healthy controls, to map peripheral blood immune signatures over time. Using the Chromium Flex assay, investigators will profile circulating immune cells at routine clinical visits and link molecular signatures to disease activity, flare, remission and treatment response. By defining a future clinical reporting format for immune activation patterns, this effort both expands 10x’s use cases into autoimmune disorders and supports the company’s long-term strategy of building recurring consumables revenue through diagnostic service partnerships.